The purpose of the study was to investigate macroscopic changes in the knee joint during intraarticular and intramuscular administration of chondroitin sulfate to laboratory rabbits in experimental osteoarthritis. Materials and methods. Experimental studies were performed on nonlinear, healthy 16 adult Chinchilla rabbits (8 males and 8 females) weighing 2.5 kg. The experimental model of osteoarthritis was based on the introduction of a solution of monoiodoacetic acid into the knee joint at the rate of 3 mg per 50 μl of sterile saline. Chondroitin sulfate was administered intraarticularly and intramuscularly. Chondroitin sulfate was administrated intraarticularly 0.24 ml 1 time in 3 days 5 times on 28, 31, 34, 37 and 40 days of the experiment and intramuscularly – 0.24 ml 1 time per day every other day for 25 days (from the 28th day of the experiment to the 53rd day). The analysis of macroscopic assessment of rabbit knee joints was performed. Results and discussion. Intramuscular and intraarticular injection of chondroitin sulfate reduces the intensity of the degenerative-dystrophic process due to the impact on inflammatory and the activation of anabolic mechanisms. Intraarticular administration of chondroitin sulfate leads to a greater increase in the level of factors of bone and cartilage formation and a greater decrease in the levels of factors of the acute phase of inflammation and factors that destroy the cartilage matrix. In our study, we attempted to visualize and compare morphological changes in intraarticular and intramuscular administration of chondroitin sulfate on the background of experimental osteoarthritis. The study highlights the possibility of using chondroitin sulfate in intraarticular administration, identified the effectiveness and impact on macroscopic changes in the tissues of the knee joint, assessed differences from intramuscular use in experimental osteoarthritis. However, in view of our research, it is not necessary to claim that all chondroitin sulfate drugs will have a similar effect. It should be remembered that the effectiveness of chondroitin sulfate depends on many factors, including the quality of raw materials. Conclusion. Intramuscular administration of chondroitin sulfate revealed a lower intensity of destructive changes in the cartilaginous surface of the knee joint, and intraarticular – the absence of cartilage destruction and defects of the cartilaginous surface, which indicates the peculiarity of the topical effect of the chondroitin sulfate

Keywords: chondroitin sulfate, intraarticular and intramuscular administration, chondroprotection, osteoarthritis

Full text: PDF (Ukr) 373K

1. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711-1712. https://doi.org/10.1016/S0140-6736(20)32230-3
2. Barnett R. Osteoarthritis. Lancet. 2018;391(10134):1985. https://doi.org/10.1016/S0140-6736(18)31064-X
3. Sacitharan PK. Ageing and osteoarthritis. Subcell Biochem. 2019;91:123-159. PMID: 30888652. https://doi.org/10.1007/978-981-13-3681-2_6
4. Vina ER, Kwoh CK. Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol. 2018;30(2):160-167. PMID: 29227353. PMCID: PMC5832048. https://doi.org/10.1097/BOR.0000000000000479
5. Vincent TL. Mechanoflammation in osteoarthritis pathogenesis. Semin Arthritis Rheum. 2019;49(3S):S36-S38. PMID: 31779850. https://doi.org/10.1016/j.semarthrit.2019.09.018
6. Mobasheri A, Rayman MP, Gualillo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2017;13(5):302-311. PMID: 28381830. https://doi.org/10.1038/nrrheum.2017.50
7. Malfait AM, Miller RE, Miller RJ. Basic mechanisms of pain in osteoarthritis: experimental observations and new perspectives. Rheum Dis Clin North Am. 2021;47(2):165-180. PMID: 33781488. https://doi.org/10.1016/j.rdc.2020.12.002
8. Allen KD, Walsh DA. Modelling pathology: pain relationships in osteoarthritis. Osteoarthritis Cartilage. 2021;29(10):1386-1388. PMID: 34329736. PMCID: PMC8518123. https://doi.org/10.1016/j.joca.2021.07.009
9. Xia B, Di Chen, Zhang J, Hu S, Jin H, Tong P. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95(6):495-505. PMID: 25311420. PMCID: PMC4747051. https://doi.org/10.1007/s00223-014-9917-9
10. Fang T, Zhou X, Jin M, Nie J, Li X. Molecular mechanisms of mechanical load-induced osteoarthritis. Int Orthop. 2021;45(5):1125-1136. PMID: 33459826. https://doi.org/10.1007/s00264-021-04938-1
11. Mao L, Wu W, Wang M, Guo JN, Li H, Zhang S, et al. Targeted treatment for osteoarthritis: drugs and delivery system. Drug Deliv. 2021;28(1):1861-1876. PMID: 34515606. PMCID: PMC8439249. https://doi.org/10.1080/10717544.2021.1971798
12. Materkowski M. Efficacy treatment of osteoarthritis with combine chondroitin and glucosamine. Ortop Traumatol Rehabil. 2021;23(3):239-244. PMID: 34190047. https://doi.org/10.5604/01.3001.0014.9842
13. Lin J, Wang L, Lin J, Liu Q. The role of extracellular vesicles in the pathogenesis, diagnosis, and treatment of osteoarthritis. Molecules. 2021;26(16):4987. PMID: 34443573. PMCID: PMC8398019. https://doi.org/10.3390/molecules26164987
14. Zhang X, He J, Wang W. Progress in the use of mesenchymal stromal cells for osteoarthritis treatment. Cytotherapy. 2021;23(6):459-470. PMID: 33736933. https://doi.org/10.1016/j.jcyt.2021.01.008
15. Franklin SP, Stoker AM, Bozynski CC, Kuroki K, Clarke KM, Johnson JK, et al. Comparison of Platelet-Rich Plasma, Stromal Vascular Fraction (SVF), or SVF with an Injectable PLGA Nanofiber Scaffold for the Treatment of Osteochondral Injury in Dogs. J Knee Surg. 2018;31(7):686-697. PMID: 28915522. https://doi.org/10.1055/s-0037-1606575
16. Rukovodstvo po provedeniyu doklinicheskih issledovaniy lekarstvennyih sredstv [Guidelines for conducting preclinical studies of medicinal product]. Pod red prof Mironova NCh. 1. M; 2012. 944 p. [Russian]
17. Guidelines for experimental (preclinical) study of new pharmacological substances. Ed by corresponding member of RAMS prof. RU Khabriev. 2005. 425 p.
18. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40:1670-9. PMID: 9324022. https://doi.org/10.1002/art.1780400917
19. Nosivets DS. Experimental models of cartilage tissue pathology. Zaporozhye medical journal. 2019;21(115):554-560. https://doi.org/10.14739/2310-1210.2019.4.173362
20. Rebrova OYu. Statisticheskiy analiz meditsinskih dannyih. Primenenie paketa prikladnyih programm Statistica [Statistical analysis of medical data. Application of the Statistica software package]. M: MediaSfera; 2002; 312 p.
21. Nosivets DS. Evaluation of the influence of chondroitin sulfate on morphometric parameters of the knee joint, pain threshold and biochemical indices in rats at experimental osteoarthritis. Ukr J Med Biol Sport. 2020;2(24):77-83. https://doi.org/10.26693/jmbs05.02.077
22. Fernández-Martín S, González-Cantalapiedra A, Muñoz F, García-González M, Permuy M, López-Peña M. Glucosamine and chondroitin sulfate: Is there any scientific evidence for their effectiveness as disease-modifying drugs in knee osteoarthritis preclinical studies? A Systematic Review from 2000 to 2021. Animals (Basel). 2021;11(6):1608. PMID: 34072407. PMCID: PMC8228516. https://doi.org/10.3390/ani11061608
23. Puigdellivol J, Comellas Berenger C, Pérez Fernández MÁ, Cowalinsky Millán JM, Carreras Vidal C, Gil Gil I, et al. Effectiveness of a dietary supplement containing hydrolyzed collagen, chondroitin sulfate, and glucosamine in pain reduction and functional capacity in osteoarthritis patients. J Diet Suppl. 2019;16(4):379-389. PMID: 29701488. https://doi.org/10.1080/19390211.2018.1461726
24. Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018;38(8):1413-1428. PMID: 29947998. https://doi.org/10.1007/s00296-018-4077-2
25. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014;78(3):184-187. PMID: 24861964. https://doi.org/10.1016/j.maturitas.2014.04.015
26. Alekseeva LI, Kashevarova NG, Taskina EA, Sharapova EP, Anikin SG, Strebkova EA, et al. [The efficacy and safety of intra-articular application of a combination of sodium hyaluronate and chondroitin sulfate for osteoarthritis of the knee: a multicenter prospective study]. Ter Arkh. 2020;92(5):46-54. [Russian]. PMID: 32598775. https://doi.org/10.26442/00403660.2020.05.000631
27. Fonsi M, El Amrani AI, Gervais F, Vincent P. Intra-Articular Hyaluronic Acid and Chondroitin Sulfate: Pharmacokinetic Investigation in Osteoarthritic Rat Models. Curr Ther Res Clin Exp. 2019;92:100573. PMID: 31956378. PMCID: PMC6957868. https://doi.org/10.1016/j.curtheres.2019.100573
28. Belyaeva EA, Avdeeva OS. [The effectiveness of complex therapy using the injectable form of chondroitin sulfate and sodium hyaluronate with osteoarthritis of the knee joint]. Ter Arkh. 2019 May 15;91(5):96-102. [Russian]. PMID: 32598683. https://doi.org/10.26442/00403660.2019.05.000213
29. Rivera F, Bertignone L, Grandi G, Camisassa R, Comaschi G, Trentini D, et al. Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study. J Orthop Traumatol. 2016 Mar;17(1):27-33. PMID: 26577936. PMCID: PMC4805636. https://doi.org/10.1007/s10195-015-0388-1
30. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808. PMID: 16495392. https://doi.org/10.1056/NEJMoa052771
31. Nosivets D, Montell E, Opryshko V. Histological changes following the administration of two different chondroitin sulfate products in experimental osteoarthritis models in rats. Eur J Clin Exp Med. 2021;19(1):23-32. https://doi.org/10.15584/ejcem.2021.1.4